Foundayo vs Tirzepatide: A Small Molecule Against a Peptide

Last reviewed 14 August 2026 · Educational, not medical advice · No sponsorships, no affiliate links

Why a peptide has to be injected and a small molecule does not

Tirzepatide is a 39-amino-acid peptide. Swallow it and your digestive tract treats it as food, which is exactly what it is built to do to peptides. Novo Nordisk got semaglutide into a tablet only by pairing it with an absorption enhancer and demanding an empty stomach and a 30-minute wait - and even then, bioavailability is low enough that the oral dose is 25 mg daily against 2.4 mg weekly by injection.

Orforglipron sidesteps the problem instead of solving it. It is not a peptide at all: it is a small molecule designed from scratch to activate the GLP-1 receptor, the first non-peptide GLP-1 agonist approved anywhere. It does not need an absorption enhancer, it does not care what is in your stomach, and it is stable at room temperature.

The catch is that no small molecule has yet been made to hit the GIP receptor as well. Every oral option on the market today is GLP-1 only, and every GIP-containing drug is an injection. That single fact explains most of the efficacy table below.

The gap, and what it is not caused by

Nine percentage points of body weight separate these molecules on cross-trial numbers - roughly 9 kg for someone starting at 100 kg. Three explanations get offered for it, and only one is right.

It is not the approved dose being lower than the trial dose. This confusion is everywhere and it is wrong. ATTAIN-1 dosed orforglipron in capsules at up to 36 mg; the marketed tablet tops out at 17.2 mg, which is a different formulation with different bioavailability, not a lower dose. Lilly maps the trial capsules of 1, 3, 6, 12, 24, and 36 mg onto tablets of 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg. The top tablet is the top trial dose.

It is not that oral delivery is inherently weaker. Oral semaglutide 25 mg reached 13.6% in OASIS-4 on the treatment-policy basis, above orforglipron, which shows a tablet can do better than 11.2%.

It is the missing GIP receptor. Compare like with like: orforglipron at 11.2% and oral semaglutide at 13.6% are both GLP-1-only agents and they cluster in the low teens. Injectable semaglutide, also GLP-1-only, sits at 13.7%. Tirzepatide, the only one with GIP, sits at 20.2%. The dividing line in the data is receptor coverage, not route of administration.

The interaction problem peptides do not have

This is the part of the chemistry comparison with the most direct clinical consequence, and it is almost never mentioned in consumer coverage.

Small molecules are cleared by liver enzymes. Orforglipron is a CYP3A4 substrate, so the label caps it at 9 mg a day - roughly half the ceiling - for anyone taking a strong CYP3A4 inhibitor. That category includes several antifungals, HIV protease inhibitors, and clarithromycin. If you need one of those, your orforglipron ceiling sits well below the dose that generated the efficacy data.

Peptides are broken down by ordinary protein catabolism and largely bypass the cytochrome system. Tirzepatide has no interactions of this kind. Its one meaningful interaction is mechanical rather than metabolic: by slowing gastric emptying it can alter the absorption of oral drugs taken alongside it, which matters most for narrow therapeutic index medicines and for oral contraceptives during titration.

Supply, price, and the argument that is not about you

Peptide manufacturing is genuinely hard to scale, and the 2023-2024 shortages made that a patient problem rather than an industry one. Small molecules are made in standard chemical plants at volumes and unit costs peptides do not reach, and they ship without a cold chain.

That should eventually show up in price, and partly already has: Foundayo starts at $149a month against Zepbound’s $299. But the advantage narrows sharply through titration. At maintenance, Foundayo is $299 to $349 and Zepbound is $449, and once you divide by result, the pill costs $458 per percentage point of weight lost against $390. The full arithmetic is in Foundayo vs Zepbound.

The larger consequence is access rather than price. A room-temperature tablet made at scale can reach markets that never got reliable injectable supply. That is a real argument for orforglipron, and it is an argument about health systems, not about which drug works better for one person.

Different rhythms need different logs

The chemistry difference shows up in your logbook before it shows up anywhere else. A weekly peptide produces a flat exposure curve, so side effects track the dose ladder: bad days after an escalation, quiet weeks at steady state. A daily small molecule produces a daily peak, so side effects track the day - and if yours cluster at a particular hour, moving when you take the tablet is a real lever that costs nothing. You will not find that pattern without timestamps.

There is a second entry that belongs in an orforglipron log and in no peptide log at all:your other medications. Because it is a CYP3A4 substrate, a course of clarithromycin or a new antifungal does not merely interact in the abstract - it caps your ceiling at 9 mg. A medication list is part of your dose record here in a way it simply is not for tirzepatide, and a two-week antibiotic course is exactly the kind of thing that gets forgotten by the next appointment.

Zenday App leads our GLP-1 app ranking at 4.55/5 for the day-to-day work - doses, food, activity, and side-effect days in one place, with side-effect management treated as a core pillar rather than a symptom list. It takes custom doses rather than only the standard ladder steps, which matters here: an orforglipron ceiling cut to 9 mg by an interacting drug is not a step on any default pen schedule. If you are tracking more than one compound, or working with compounded product rather than a branded pen, Regimen models over 150 compounds with real-time pharmacokinetic curves and gives away the medication-level chart that others paywall.

What the evidence does not show

• No head-to-head trial exists. Every comparison here lines up ATTAIN-1 and ATTAIN-2 against SURMOUNT and SURPASS trials with different populations and comparators.
• Orforglipron has no outcome data. No cardiovascular trial, no kidney, liver, or sleep apnea data. Tirzepatide has SURPASS-CVOT and a sleep apnea indication.
• No long-term safety record for non-peptide GLP-1 agonists. Orforglipron is the first approved. Its class has no decade behind it.
• No persistence data. The strongest theoretical argument for a pill is that more people stay on it. Foundayo launched in April 2026 and nobody has measured whether that is true.

How to choose

• Maximum weight loss: tirzepatide. The receptor difference is not something the oral class can currently match.
• You will not inject: orforglipron, and the comparison that matters for you is against the Wegovy pill, not against tirzepatide.
• You take a strong CYP3A4 inhibitor: tirzepatide, unless you accept a halved ceiling.
• You have type 2 diabetes or sleep apnea: tirzepatide has the indications. Orforglipron has none beyond weight.
• No refrigeration, frequent travel, or unreliable supply: orforglipron removes problems that have nothing to do with efficacy and everything to do with whether treatment continues.

Method and sources

Orforglipron figures come from ATTAIN-1 and ATTAIN-2 as published and the US prescribing information, using treatment-regimen estimands rather than the efficacy estimands quoted in approval press releases. Tirzepatide figures come from SURMOUNT-5, SURMOUNT-2, SURPASS-2, and SURPASS-CVOT. Oral semaglutide figures come from OASIS-4. Prices are US manufacturer self-pay rates read on 14 August 2026. We take no money from any manufacturer and run no affiliate links. See also semaglutide vs tirzepatide and Foundayo vs Zepbound.